Evidence map›Paper›PMID 37043116›Full record

ReviewCurrent oncology reports2023

First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology.

Vibor Milunović, Inga Mandac Smoljanović, Martina Bogeljić Patekar, Viktor Zatezalo, Marin Kursar, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić, Slavko Gašparov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vibor MilunovićDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia. vibor96@gmail.com.ORCID 0000-0003-0069-6688
Inga Mandac SmoljanovićDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia.
Martina Bogeljić PatekarDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia.
Viktor ZatezaloDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia.
Marin KursarDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia.
Delfa Radić-KrištoDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia.
Slobodanka Ostojić KolonićDivision of Hematology, Clinical Hospital Merkur, Zajčeva 19, 10000, Zagreb, Croatia.
Slavko GašparovSchool of Medicine, University of Zagreb, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeof reviewThe main aim of this review is to summarize first-line therapy of nodal T-cell non-Hodgkin lymphoma. RECENT

findingsCurrent treatment with CHOP chemotherapy results in poor outcomes in the majority of patients. However, there are advances within the field. First breakthrough is the ECHELON-2 trial which showed that the addition of brentuximab vedotin improves outcomes in anaplastic large cell lymphoma. However, other types of peripheral T-cell non-Hodgkin lymphoma were underrepresented with optimal treatment not known. Second breakthrough is an increase of autologous stem cell transplantation usage in the first complete metabolic remission, except in ALK + anaplastic large cell lymphoma, offering better disease control. Despite advances in the field, CHOP remains the standard treatment for the majority of these lymphomas, but multiple trials are underway with the aim to improve this unmet need in hematology and, hopefully, leading us to a new era in the treatment of peripheral T-cell lymphomas.

Indexed as

HematologyHematopoietic Stem Cell TransplantationImmunoconjugatesLymphoma, Large-Cell, AnaplasticHumansT-LymphocytesTransplantation, AutologousImmunoconjugatesAlemtuzumabBrentuximab vedotinCHOP protocolHematopoietic stem cell transplantationHistone deacetylase inhibitorsPeripheral T-cell lymphoma

Identifiers

PMID37043116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.